I think you need to be asking two questions. Why did Immune do financing with Discover Growth Fund? Secondly. Why are they selling Ceplene first? Why not sell IMNP first? What was the reasoning behind that move? I think it’s pretty obvious why. Then add one more question. Why not accept the deal with that German company? I agree with crooked Kirkland, why aren’t they naming Company A, but they’ll name other companies? Why not think that Bert deal was good and then instead take a much lower offer for Cytovia?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.